The FDA has authorized a first-of-its-kind therapeutic device that delivers tumor-treating fields for adults with locally advanced pancreatic cancer. The approval offers a new non-invasive option to extend...
The FDA approval expands frontline treatment options for adults with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant, based on randomized trial data showing...
In a large global phase 3 trial, investigators evaluated whether adding the CD19-targeted monoclonal antibody tafasitamab to the established lenalidomide–rituximab regimen could improve outcomes for adults...
A pooled analysis of 4 MagnetisMM trials evaluated dosing strategies for elranatamab, a BCMA-CD3 bispecific antibody, to identify the optimal regimen that mitigates cytokine release syndrome in patients...
An open-label, randomized trial found that daratumumab and hyaluronidase-fihj administered subcutaneously improved the risk of disease progression or death in patients with multiple myeloma. As a result,...
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
A phase 1b–2 trial published in The New England Journal of Medicine evaluated the combination of two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed or refractory multiple...
For oncologists considering immunotherapy sequencing, a Nature report from MD Anderson Cancer Center in Houston, TX, suggests that receipt of a SARS-CoV-2 mRNA vaccine near the start of immune checkpoint...
